Sponsors (2)
The bill aims to clarify and broaden patent-eligibility (boosting incentives and predictability for many inventors and biotech firms) while also tightening some limits on trivial computer-based claims — but it risks more litigation, lower-quality patents on routine implementations, and altered incentives for biotech commercialization.
Researchers, inventors, and biotech firms: clearer patent-eligibility rules make it easier to obtain patents on useful inventions and on purified/altered natural materials (while excluding unmodified human genes), preserving incentives to commercialize new technologies.
Patent applicants, tech workers, and examiners: more predictable and consistent patent review because courts must assess claims as a whole and statutory guidance narrows attempts to claim abstract ideas via trivial machine language, reducing inconsistent rejections and improving examination reliability.
Software developers, startups, and the public: explicit limits on when adding generic computer steps can revive eligibility reduces the scope for low-quality, trivial software patents and helps protect against overly broad abstract-idea claims.
Small businesses, software firms, and inventors: broader eligibility could allow patents on a wider range of business, software, and social processes (unless purely economic or mental), raising the risk of more litigation, licensing costs, and barriers to competition.
Startups, developers, and downstream users: preventing courts and the USPTO from considering whether claim elements are conventional may enable patents on routine implementations, increasing low-quality patents and follow-on licensing or injunction risks.
Biotech companies, hospitals, and health systems: excluding unmodified human genes and natural materials from patentability reduces the ability to secure proprietary claims on naturally-derived products and could affect investment, commercialization strategies, and pricing.
Based on analysis of 4 sections of legislative text.
Replaces judicial §101 exceptions with a statutory rule broadly restoring patent eligibility for useful inventions while listing narrow ineligible categories.
Official title: To amend title 35, United States Code, to address matters relating to patent subject matter eligibility, and for other purposes.
Introduced May 1, 2025 by Kevin Kiley · Last progress May 1, 2025
Restores a broad statutory rule that most inventions that are useful processes, machines, manufactures, compositions of matter, or useful improvements are eligible for U.S. patents while explicitly listing narrow categories that remain ineligible (e.g., pure mathematical formulas, purely mental processes, unmodified human genes and natural materials as they exist in nature, and largely economic or artistic processes). It removes judicially created eligibility exceptions as the basis for §101 rejections, directs courts to decide eligibility by looking at claims as a whole without relying on novelty, nonobviousness, or written‑description rules, and adds definitions and procedural rules for how eligibility questions are to be handled in patent and infringement litigation.